KAMRON FARIBA: Open Payments
NPI 1407315864 · GLENDORA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$879 in 34 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $879
Food & beverage: $770Education: $109
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $195 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $158 |
| Teva Pharmaceuticals USA, Inc. | 4 | $144 |
| Alkermes, Inc. | 1 | $122 |
| Neurocrine BioSciences, Inc. | 2 | $66 |
| Janssen Pharmaceuticals, Inc | 3 | $54 |
| E.R. Squibb & Sons, L.L.C. | 2 | $42 |
| ABBVIE INC. | 2 | $33 |
| Indivior Inc. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
Products named: REXULTI, CAPLYTA, LYBALVI, INGREZZA, INVEGA SUSTENNA, COBENFY, VRAYLAR, SUBLOCADE.
Industry payments across CA — which companies pay providers there.
